Patents by Inventor Charles A. Flentge

Charles A. Flentge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV protease inhibiting compounds
    Publication number: 20050131017
    Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
    Type: Application
    Filed: December 11, 2003
    Publication date: June 16, 2005
    Inventors: David DeGoey, Charles Flentge, William Flosi, David Grampovnik, Dale Kempf, Larry Klein
  • HIV protease inhibiting compounds
    Publication number: 20050131042
    Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
    Type: Application
    Filed: December 11, 2003
    Publication date: June 16, 2005
    Inventors: Charles Flentge, Hui-Ju Chen, David DeGoey, William Flosi, David Grampovnik, Peggy Huang, Dale Kempf, Larry Klein, Allan Krueger, Darold Madigan, John Randolph, Minghua Sun, Ming Yeung, Chen Zhao
  • Anti-infective agents
    Publication number: 20050107364
    Abstract: Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    Type: Application
    Filed: August 24, 2004
    Publication date: May 19, 2005
    Inventors: Douglas Hutchinson, John Bellettini, David Betebenner, Richard Bishop, Thomas Borchardt, Todd Bosse, Russell Cink, Charles Flentge, Bradley Gates, Brian Green, Mira Hinman, Peggy Huang, Larry Klein, Allan Krueger, Daniel Larson, M. Leanna, Dachun Liu, Darold Madigan, Keith McDaniel, John Randolph, Todd Rockway, Teresa Rosenberg, Kent Stewart, Vincent Stoll, Rolf Wagner, Ming Yeung
  • Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassy
    Patent number: 5354693
    Abstract: A fluorescence polarization immunoassay (FPIA) for detecting the presence of one or more amphetamine-class analytes in a test sample is provided. The immunoassay uses competition between the analyte and a fluorescently labeled tracer for the binding site on an antibody specific for phenethylamine derivatives. The concentration of amphetamine-class analyte in the sample determines the amount of tracer that binds to the antibody. The amount of tracer-antibody complex formed can be quantitatively measured and is inversely proportional to the quantity of analyte in the test sample. The invention relates to tracers, to immunogens used to elicit antibodies for use as assay reagents, and to assay kits incorporating these tracers and assay reagents.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: October 11, 1994
    Assignee: Abbott Laboratories
    Inventors: Paul J. Brynes, Donald D. Johnson, Cynthia M. Molina, Charles A. Flentge, Patrick F. Jonas
  • Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
    Patent number: 5248791
    Abstract: A fluorescence polarization immunoassay (FPIA) for detecting the presence of one or more amphetamine-class analytes in a test sample is provided. The immunoassay uses competition between the analyte and a fluorescently labeled tracer for the binding site on an antibody specific for phenethylamine derivatives. The concentration of amphetamine-class analyte in the sample determines the amount of tracer that binds to the antibody. The amount of tracer/antibody complex formed can be quantitatively measured and is inversely proportional to the quantity of analyte in the test sample. The invention relates to tracers, to immunogens used to elicit antibodies for use as assay reagents, and to assay kits incorporating these tracers and assay reagents.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: September 28, 1993
    Assignee: Abbott Laboratories
    Inventors: Paul J. Brynes, Donald D. Johnson, Cynthia M. Molina, Charles A. Flentge, Patrick F. Jonas
  • Reagents for an amphetamine-class fluorescence polarization immunoassay
    Patent number: 5101015
    Abstract: A fluorescence polarization immunoassay (FPIA) for detecting the presence of one or more amphetamine-class analytes in a test sample is provided. The immunoassay uses competition between the analyte and a fluorescently labeled tracer for the binding site on an antibody specific for phenethylamine derivatives. The concentration of amphetamine-class analyte in the sample determines the amount of tracer that binds to the antibody. The amount of tracer/antibody complex formed can be quantitatively measured and is inversely proportional to the quantity of analyte in the test sample. The invention relates to tracers, to immunogens used to elicit antibodies for use as assay reagents, and to assay kits incorporating these tracers and assay reagents.
    Type: Grant
    Filed: April 10, 1989
    Date of Patent: March 31, 1992
    Assignee: Abbott Laboratories
    Inventors: Paul J. Brynes, Donald D. Johnson, Cynthia M. Molina, Charles A. Flentge, Patrick F. Jonas
  • N-substituted dibenz[b,f]azepine salts
    Patent number: 4559173
    Abstract: Carbamazepine-thiophosphonate conjugates for use as enzyme inhibitors having the formula: ##STR1## wherein Z is a biologically compatible counter ion, n is an integer from 2 to 6 and R and R.sub.1 are each lower alkyl.
    Type: Grant
    Filed: November 4, 1983
    Date of Patent: December 17, 1985
    Assignee: Abbott Laboratories
    Inventor: Charles A. Flentge
  • Phenobarbital enzyme inhibitors
    Patent number: 4543412
    Abstract: Phenobarbital conjugates for use as enzyme inhibitors having the formula: ##STR1## wherein Z is a biologically compatible counter ion, n and m is an integer from 2 to 6 and R and R.sub.1 are each lower alkyl.
    Type: Grant
    Filed: November 4, 1983
    Date of Patent: September 24, 1985
    Assignee: Abbott Laboratories
    Inventors: Charles A. Flentge, Thomas R. Herrin
  • Substituted theophylline salts
    Patent number: 4451652
    Abstract: The present disclosure relates to a novel class of substituted theophylline salts useful as reagents in an irreversible enzyme inhibitor immunoassay for theophylline. The use of such reagents increases the sensitivity of the theophylline assay.
    Type: Grant
    Filed: May 24, 1982
    Date of Patent: May 29, 1984
    Assignee: Abbott Laboratories
    Inventors: Charles A. Flentge, Curtis L. Kirkemo